Table 1.
Patient and Tumor Baseline Characteristics
| Characteristics | Overall Population (N = 20) |
|---|---|
| Median age | 64 |
| Female, n (%) | 15 (75) |
| Histology, n (%) | |
| Adenocarcinoma | 18 (90) |
| NSCLC (NOS) | 2 (10) |
| EGFR mutation at baseline, n (%) | |
| EGFR L858R | 11 (55) |
| EGFR exon19del | 9 (45) |
| MET amplification detection method (n) | |
| FISH | 14 |
| NGS on tissue | 10 |
| ctDNA | 3 |
| Average MET GCN | 13.6 |
| Onset of MET amp, n (%) | |
| After progression on frontline osimertinib | 9 (45) |
| After progression on two previous lines of therapy | 3 (15) |
| After progression on three previous lines of therapy | 2 (10) |
| After progression on four previous lines of therapy | 1 (5) |
| Median previous lines of therapy | 2 |
| Patients received previous platinum-based chemotherapy (n) | |
| Chemotherapy with immunotherapy | 6 |
| Chemotherapy | 6 |
| Baseline brain metastases before double TKIs (n) | |
| Present, treated | 7 |
| Present, untreated | 2 |
| Combination used (m) | |
| Crizotinib plus osimertinib | 12 |
| Capmatinib plus osimertinib | 6 (3 after crizotinib + osimertinib) |
| Savolitinib plus osimertinib | 3 |
| Tepotinib plus osimertinib | 2 |
ctDNA, circulating tumor DNA; exon19del, exon 19 deletion; FISH, fluorescence in situ hybridization; GCN, gene copy number; MET amp, MET amplification; NGS, next-generation sequencing; NOS, not otherwise specified; TKI, tyrosine kinase inhibitor.